Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Pfizer Inc. (PFE) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Inc. (PFE) - free report >>
Image: Bigstock
Allergan (AGN) Gets FDA Nod for Avycaz Label Expansion
Allergan plc announced that the FDA has expanded the label of its antibiotic, Avycaz. The label now includes phase III data on Avycaz plus metronidazole for the treatment of complicated intra-abdominal infections (cIAI) caused by designated susceptible microorganisms. The label has also been updated to include phase III data from a subset of patients with infections due to ceftazidime-nonsusceptible (CAZ-NS) pathogens, as well as a subset of patients who had pathogens producing certain extended-spectrum beta-lactamases (ESBLs).
Allergan, which is selling its generics business to Teva Pharmaceutical Industries Limited (TEVA - Free Report) for net cash/equity proceeds of about $36 billion, is working on expanding and strengthening its branded business. The company has more than 70 projects in mid-to-late stage development and is also working on expanding the labels of existing products.
Earlier this month, the FDA had accepted for review a supplemental New Drug Application (sNDA) for the 72 mcg dose of Linzess for use in the treatment of adults with chronic idiopathic constipation (CIC). A response from the agency should be out early next year.
Meanwhile, interesting pipeline candidates include abicipar (age related macular degeneration), rapastinel (depression), ubrogepant (migraine), XEN45 (glaucoma) and tavilermide (dry eye) among others.
Although the termination of the combination agreement with Pfizer, Inc. (PFE - Free Report) was disappointing, we remain optimistic about the stand-alone company’s growth prospects. We expect Allergan to continue pursuing tuck-in acquisitions and buying R&D assets.
Allergan is a Zacks Rank #3 (Hold) stock. Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) is a better-ranked stock in the healthcare sector with a Zacks Rank #1 (Strong Buy). Pfizer is also a Zacks Rank #1 stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>